Drug Treatment of obesity: Established and emerging therapies

Mini-Reviews in Medicinal Chemistry

Volumn 9, Issue 6, 2009, Pages 664-673

  Isidro, M Luisa ^a   Cordido, Fernando ^a,b  

^a HOSPITAL JUAN CANALEJO   (Spain)

^b UNIVERSITY OF A CORUÑA   (Spain)

Author keywords

Drug treatment; Ghrelin; Leptin; Obesity; Orlistat; Rimonabant; Sibutramine

Indexed keywords

ANGIOPEPTIN; ANTIOBESITY AGENT; BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; CILIARY NEUROTROPHIC FACTOR; DEXFENFLURAMINE; EXENDIN 4; FENFLURAMINE; GHRELIN RECEPTOR ANTAGONIST; GLUCAGON LIKE PEPTIDE 1; HUMAN GROWTH HORMONE[176-191][176 TYROSINE]; LEPTIN; LIRAGLUTIDE; MELANIN CONCENTRATING HORMONE RECEPTOR 1 ANTAGONIST; MELANOCORTIN RECEPTOR AGONIST; NEUROPEPTIDE Y RECEPTOR ANTAGONIST; OCTREOTIDE; OXYNTOMODULIN; PEPTIDE YY [3-36]; PHENTERMINE; PLACEBO; RECOMBINANT CILIARY NEUROTROPHIC FACTOR; RECOMBINANT GROWTH HORMONE; RIMONABANT; RO 27 3225; SEROTONIN 6 ANTAGONIST; SEROTONIN AGONIST; SIBUTRAMINE; SOMATOSTATIN; TETRAHYDROLIPSTATIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; PEPTIDE;

ABDOMINAL PAIN; ABNORMAL FECES COMPOSITION; ANXIETY; CLINICAL TRIAL; DEFECATION URGENCY; DEPRESSION; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME INHIBITION; FECES INCONTINENCE; FLATULENCE; HUMAN; HYPERTENSION; INSOMNIA; LOW CALORY DIET; MENTAL DISEASE; NAUSEA; NONHUMAN; OBESITY; RESTLESSNESS; REVIEW; SIDE EFFECT; TACHYCARDIA; ANIMAL; ANOREXIA; DRUG EFFECT; EATING; ENERGY METABOLISM; METABOLISM;

ANIMALS; ANOREXIA; ANTI-OBESITY AGENTS; EATING; ENERGY METABOLISM; HUMANS; OBESITY; PEPTIDES;

EID: 69249217866     PISSN: 13895575     EISSN: None     Source Type: Journal    
DOI: 10.2174/138955709788452739     Document Type: Review

References (88)

1. Tremblay, A.; Doucet, E. Obesity: a disease or a biological adaptation? Obes. Rev., 2000, 1, 27-35.
2. Li, Z.; Maglione, M.; Tu, W.; Mojica, W.; Arterburn, D.; Shugarman, L.R.; Hilton, L.; Suttorp, M.; Solomon, V.; Shekelle, P.G.; Morton, S.C. Meta-analysis: pharmacologic treatment of obesity. Ann. Intern. Med., 2005, 142, 532-46.
3. Rucker, D.; Padwal, R; Li, S.K.; Curioni, C.; Lau, D.C. Long term pharmacotherapy for obesity and overweight: updated metaanalysis. BMJ, 2007, 335, 1194-9.
4. Christensen, R.; Kristensen, P.K.; Bartels, E.M.; Bliddal, H.; Astrup, A. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet, 2007, 370, 1706-13.
5. Torgerson, J.S.; Hauptman, J.; Boldrin, M.N.; Sjöström, L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care, 2004, 27, 155-61.
6. Bërubë-Parent, S.; Prud'homme, D.; St-Pierre, S.; Doucet, E; Tremblay, A. Obesity treatment with a progressive clinical tritherapy combining sibutramine and a supervised diet - exercise intervention. Int. J. Obes., 2001, 25, 1144-53.
7. Bellocchio, L.; Cervino, C.; Pasquali, R.; Pagotto, R. The endocannabinoid system and energy metabolism. J. Neuroendocrinol., 2008, 20, 850-7.
8. Foster-Schubert, K.E.; Cummings, D.E. Emerging therapeutic strategies for obesity. Endocr. Rev., 2006, 27, 779-93.
9. Klok, M.D.; Jakobsdottir, S.; Drent, M.L. The role of leptin and ghrelin in the regulation of food intake and body weight in humans: a review. Obes. Rev., 2007, 8, 21-34.
10. Considine, R.V.; Sinha, M.K.; Heiman, M.L.; Kriauciunas, A.; Stephens, T.W.; Nyce, M.R.; Ohannesian, J.P.; Marco, C.C.; McKee, L.J.; Bauer, T.L.; Caro, J.F. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N. Engl. J. Med., 1996, 334, 292-5.
11. Schwartz, M.W., Seeley, R.J., Campfield, L.A., Burn, P., Baskin, D.G. Identification of targets of leptin action in rat hypothalamus. J. Clin. Invest., 1996, 98, 1101-6.
12. Otvos, L. Jr.; Terrasi. M.; Cascio, S.; Cassone, M.; Abbadessa, G.; De Pascali, F.; Scolaro, L.; Knappe, D.; Stawikowski, M.; Cudic, P.; Wade, J.D.; Hoffmann, R.; Surmacz, E. Development of a pharmacologically improved peptide agonist of the leptin receptor. Biochim. Biophys. Acta, 2008, 1783, 1745-54.
13. Banks, W.A. Leptin transport across the blood-brain barrier: implications for the cause and treatment of obesity. Curr. Pharm. Des., 2001, 7, 125-33.
14. El-Haschimi, K.; Pierroz, D.D.; Hileman, S.M.; Bjorbaek, C.; Flier, J.S. Two defects contribute to hypothalamic leptin resistance in mice with diet-induced obesity. J. Clin. Invest., 2000, 105, 1827- 32.
15. Huszar, D.; Lynch, C.A.; Fairchild-Huntress, V.; Dunmore, J.H.; Fang, Q.; Berkemeier, L.R.; Gu, W.; Kesterson, R.A.; Boston, B.A.; Cone, R.D.; Smith, F.J.; Campfield, L.A.; Burn, P.; Lee, F. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell, 1997, 88, 131-41.
16. Chen, A.S.; Marsh, D.J.; Trumbauer, M.E.; Frazier, E.G.; Guan, X.M.; Yu, H.; Rosenblum, C.I.; Vongs, A.; Feng, Y.; Cao, L.; Metzger, J.M.; Strack, A.M.; Camacho, R.E.; Mellin, T.N.; Nunes, C.N.; Min, W.; Fisher, J.; Gopal-Truter, S.; MacIntyre, D.E.; Chen, H.Y.; Van der Ploeg, L.H. Inactivation of the mouse melanocortin- 3 receptor results in increased fat mass and reduced lean body mass. Nat. Genet., 2000, 26, 97-102.
17. Benoit, S.C.; Schwartz, M.W.; Lachey, J.L.; Hagan, M.M.; Rushing, P.A.; Blake, K.A.; Yagaloff, K.A.; Kurylko, G.; Franco, L.; Danhoo, W.; Seeley, R.J. A novel selective melanocortin-4 receptor agonist reduces food intake in rats and mice without producing aversive consequences. J. Neurosci., 2000, 20, 3442-8.
18. Mancini, M.C.; Halpern, A. Investigational therapies in the treatment of obesity. Expert Opin. Invest. Drugs, 2006, 15, 897-915.
19. Coll, A.P. Effects of pro-opiomelanocortin (POMC) on food intake and body weight: mechanisms and therapeutic potential? Clin. Sci., 2007, 113, 171-82.
20. Jaworski, K.; Ahmadian, M.; Duncan, R.E.; Sarkadi-Nagy, E.; Varady, K.A.; Hellerstein, M.K., Lee, H.Y.; Samuel, V.T.; Shulman, G.I.; Kim, K.H.; de Val, S.; Kang, C.; Sul, H.S. AdPLA ablation increases lipolysis and prevents obesity induced by high-fat feeding or leptin deficiency. Nat. Med., 2009, 15, 159-68.
21. ALS CNTF Treatment Study Group. A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. Neurology, 1996, 46, 1244-9.
22. Ettinger, M.P.; Littlejohn, T.W.; Schwartz, S.L.; Weiss, S.R.; McIlwain, H.H.; Heymsfield, S.B.; Bray, G.A.; Roberts, W.G.; Heyman, E.R.; Stambler, N.; Heshka, S.; Vicary, C.; Guler, H.P. Recombinant variant of ciliary neurotrophic factor for weight loss in obese adults: a randomized, dose-ranging study. JAMA, 2003,289, 1826-32.
23. Febbraio, M.A. gp130 receptor ligands as potential therapeutic targets for obesity. J. Clin. Invest., 2007, 117, 841-9.
24. Matthews, V.B.; Febbraio, M.A. CNTF: a target therapeutics for obesity-related metabolic disease? J. Mol. Med., 2008, 86, 353-61.
25. Tecott, L.H.; Sun, L.M.; Akana, S.F.; Strack, A.M.; Lowenstein, D.H.; Dallman, M.F.; Julius, D. Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors. Nature, 1995, 374, 542- 6.
26. Nonogaki, K.; Strack, A.M.; Dallman, M.F.; Tecott, L.H. Leptinindependent hyperphagia and type 2 diabetes in mice with a mutated serotonin 5-HT2C receptor gene. Nat. Med., 1998, 4, 1152-6.
27. Heisler, L.K.; Jobst, E.E.; Sutton, G.M.; Zhou, L.; Borok, E.; Thornton-Jones, Z.; Liu, H.Y.; Zigman, J.M.; Balthasar, N.; Kishi, T.; Lee, C.E.; Aschkenasi, C.J.; Zhang, C.Y.; Yu, J.; Boss, O.; Mountjoy, K.G.; Clifton, P.G.; Lowell, B.B.; Friedman, J.M.; Horvath, T.; Butler, A.A.; Elmquist, J.K.; Cowley, M.A. Serotonin reciprocally regulates melanocortin neurons to modulate food intake. Neuron, 2006, 51, 239-49.
28. Halford, J.C.; Harrold, J.A.; Boyland, E.J.; Lawton, C.L.; Blundell, J.E. Serotonergic drugs : effects on appetite expression and use for the treatment of obesity. Drugs, 2007, 67, 27-55.
29. Wacker, D.A.; Miller, K.J. Agonists of the serotonin 5-HT2C receptor: preclinical and clinical progression in multiple diseases. Curr. Opin. Drug Discov. Dev., 2008, 11, 438-45.
30. Holenz, J.; Mercé, R.; Díaz, J.L.; Guitart, X.; Codony, X.; Dordal, A.; Romero, G.; Torrens, A.; Mas, J.; Andaluz, B.; Hernández, S.; Monroy, X.; Sánchez, E.; Hernández, E.; Përez, R.; Cubí, R.; Sanfeliu, O.; Buschmann, H. Medicinal chemistry driven approaches toward novel and selective serotonin 5-HT6 receptor ligands. J. Med. Chem., 2005, 48, 1781-95.
31. Holenz, J.; Pauwels, P.J.; Díaz, J.L.; Mercé, R.; Codony, X.; Buschmann, H. Medicinal chemistry strategies to 5-HT(6) receptor ligands as potential cognitive enhancers and antiobesity agents. Drug Discov. Today, 2006, 11, 283-99.
32. Heal, D.J.; Smith, S.L.; Fisas, A.; Codony, X.; Buschmann, H. Selective 5-HT6 receptor ligands: progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders. Pharmacol. Ther., 2008, 117, 207-31.
33. Kamiji, M.M.; Inui, A. Neuropeptide y receptor selective ligands in the treatment of obesity. Endocr. Rev., 2007, 28, 664-84.
34. Luthin, D.R. Anti-obesity effects of small molecule melanin-concentrating hormone receptor 1 (MCHR1) antagonists. Life Sci., 2007, 81, 423-40.
35. Kym, P.R.; Judd A.S.; Lynch, J.K.; Iyengar, R.; Vasudevan, A.; Souers, A.J. Lead optimization strategies and tactics applied to the discovery of melanin concentrating hormone receptor 1 antagonists. Curr. Top. Med. Chem., 2007, 7, 1471-88.
36. Rivera, G.; Bocanegra-García, V.; Galiano, S.; Cirauqui, N.; Ceras, J.; Përez, S.; Aldana, I.; Monge, A. Melanin-concentrating hormone receptor 1 antagonists: a new perspective for the pharmacologic treatment of obesity. Curr. Top. Med. Chem., 2008, 15, 1025-43.
37. Lustig, R.H.; Greenway, F.; Velasquez-Mieyer, P.; Heimburger, D.; Schumacher, D.; Smith, D.; Smith, W.; Soler, N.; Warsi, G.; Berg, W.; Maloney, J.; Benedetto, J.; Zhu, W.; Hohneker, J. A multicenter, randomized, double-blind, placebo-controlled, dosefinding trial of a long-acting formulation of octreotide in promoting weight loss in obese adults with insulin hypersecretion. Int. J. Obes. (Lond.), 2006, 30, 331-41.
38. Velasquez-Mieyer, P.A.; Cowan, P.A.; Arheart, K.L.; Buffington, C.K.; Spencer, K.A.; Connelly, B.E.; Cowan, G.W.; Lustig, R.H. Suppression of insulin secretion is associated with weight loss and altered macronutrient intake and preference in a subset of obese adults. Int. J. Obes. Relat. Metab. Disord., 2003, 27, 219-26.
39. Huda, M.S.; Wilding, J.P.; Pinkney, J.H. Gut peptides and the regulation of appetite. Obes. Rev., 2006, 7, 163-82.
40. Murphy, K.G.; Dhillo, W.S.; Bloom, S.R. Gut peptides in the regulation of food intake and energy homeostasis. Endocr. Rev., 2006, 27, 719-27.
41. Cummings, D.E.; Overduin, J. Gastrointestinal regulation of food intake. J. Clin. Invest., 2007, 117, 13-23.
42. Field, B.C.; Wren, A.M.; Cooke, D.; Bloom, S.R. Gut hormones as potential new targets for appetite regulation and the treatment of obesity. Drugs, 2008, 68, 147-63.
43. Meier, J.J.; Nauck, M.A. Glucagon-like peptide 1(GLP-1) in biology and pathology. Diabetes Metab. Res. Rev., 2005, 21, 91-117.
44. Rodríguez de Fonseca, F.; Navarro, M.; Álvarez, E.; Roncero, I.; Chowen, J.A.; Maestre, O.; Gómez, R.; Muñoz, R.M.; Eng, J.; Blázquez, E. Peripheral versus central effects of glucagon-like peptide- 1 receptor agonists on satiety and body weight loss in Zucker obese rats. Metabolism, 2000, 49, 709-17.
45. Flint, A.; Raben, A.; Astrup, A.; Holst, J.J. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J. Clin. Invest., 1998, 101, 515-20.
46. Gutzwiller, J.P.; Göke, B.; Drewe, J.; Hildebrand, P.; Ketterer, S.; Handschin, D.; Winterhalder, R., Conen, D.; Beglinger, C. Glucagon- like peptide-1: a potent regulator of food intake in humans. Gut, 1999, 44, 81-6.
47. Amori, R.E.; Lau, J.; Pittas, A.G. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA, 2007, 298, 194-206.
48. Van Gaal, L.F.; Gutkin, S.W.; Nauk, M.A. Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitus: glucagon- like peptide 1 receptor agonists or insulin for patients with inadequate glycemic control? Eur. J. Endocrinol., 2008, 158, 773-84.
49. Meier, J.J.; Gallwitz, B.; Schmidt, W.E.; Nauck, M.A. Glucagonlike peptide 1 as a regulator of food intake and body weight: therapeutic perspectives. Eur. J. Pharmacol., 2002, 440, 269-79.
50. Batterham, R.L.; Cowley, M.A.; Small, C.J.; Herzog, H.; Cohen, M.A., Dakin, C.L.; Wren, A.M.; Brynes, A.E.; Low, M.; Ghatei, M.A.; Cone, R.D.; Bloom, S.R. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature, 2002, 418, 650-4.
51. Acuã-Goycolea, C.; van den Pol, A.N. Peptide YY(3-36) inhibits both anorexigenic proopiomelanocortin and orexigenic neuropeptide Y neurons: implications for hypothalamic regulation of energy homeostasis. J. Neurosci., 2005, 25, 10510-9.
52. Wynne, K.; Bloom, S.R. The role of oxyntomodulin and peptide tyrosine-tyrosine (PYY) in appetite control. Nat. Clin. Pract. Endocrinol. Metab., 2006, 2, 612-20.
53. Vincent, R.P.; le Roux, C.W. The satiety hormone peptide YY as a regulator of appetite. J. Clin. Pathol., 2008, 61, 548-52.
54. Përez-Fontán, M.; Cordido, F.; Rodríguez-Carmona, A.; Penín, M.; Díaz-Cambre, H.; López-Muñiz, A.; Sangiao-Alvarellos, S., García-Buela, J. García-Buela, J. Short-term regulation of peptide YY secretion by a mixed meal or peritoneal glucose-based dialysate in patients with chronic renal failure. Nephrol. Dial. Transplant., 2008, 23, 3696-703.
55. Batterham, R.L.; Cohen, M.A.; Ellis, S.M.; Le Roux, C.W.; Withers, D.J.; Frost, G.S.; Ghatei, M.A.; Bloom, S.R. Inhibition of food intake in obese subjects by peptide YY3-36. N. Engl. J. Med., 2003, 349, 941-8.
56. Ashby, D.; Bloom, S.R. Recent progress in PYY research - an update report for 8th NPY meeting. Peptides, 2007, 28, 198-202.
57. Gantz, I.; Erondu, N.; Mallick, M.; Musser, B.; Krishna, R.; Tanaka, W.K.; Snyder, K.; Stevens, C.; Stroh, M.A.; Zhu, H.; Wagner, J.A.; Macneil, D.J., Heymsfield, S.B.; Amatruda, J.M. Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults. J. Clin. Endocrinol. Metab., 2007, 92, 1754-7.
58. Përez-Fontán, M.; Cordido, F.; Rodríguez-Carmona, A.; Peteiro, J.; García-Naveiro, R.; García-Buela, J. Plasma ghrelin levels in patients undergoing haemodialysis and peritoneal dialysis. Nephrol. Dial. Transplant., 2004, 19, 2095-100.
59. Përez-Fontán, M.; Cordido, F.; Rodríguez-Carmona, A.; García- Naveiro, R.; Isidro, M.L.; Villaverde, P.; García-Buela, J. Acute plasma ghrelin and leptin responses to oral feeding or intraperitoneal hypertonic glucose-based dialysate in patients with chronic renal failure. Kidney Int., 2005, 68, 2877-85.
60. Druce, M.R.; Wren, A.M.; Park, A.J.; Milton, J.E.; Patterson, M.; Frost, G.; Ghatei, M.A.; Small, C.; Bloom, S.R. Ghrelin increases food intake in obese as well as lean subjects. Int. J. Obes. (Lond.), 2005, 29, 1130-6.
61. English, P.J.; Ghatei, M.A.; Malik, I.A.; Bloom, S.R.; Wilding, J.P. Food fails to suppress ghrelin levels in obese humans. J. Clin. Endocrinol. Metab., 2002, 87, 2984-7.
62. Zhao, H.; Xin, Z.; Liu, G.; Schaefer, V.G.; Falls, H.D.; Kaszubska, W.; Collins, C.A.; Sham, H.L. Discovery of tetralin carboxamide growth hormone secretagogue receptor antagonists via scaffold manipulation. J. Med. Chem., 2004, 47, 6655-7.
63. Rudolph, J.; Esler, W.P.; O'connor, S.; Coish, P.D.; Wickens, P.L.; Brands, M.; Bierer, D.E.; Bloomquist, B.T.; Bondar, G.; Chen, L.; Chuang, C.Y.; Claus, T.H.; Fathi, Z.; Fu, W.; Khire, U.R.; Kristie, J.A.; Liu, X.G.; Lowe, D.B.; McClure, A.C.; Michels, M.; Ortiz, A.A.; Ramsden, P.D.; Schoenleber, R.W.; Shelekhin, T.E.; Vakalopoulos, A.; Tang, W.; Wang, L.; Yi, L.; Gardell, S.J.; Livingston, J.N.; Sweet, L.J.; Bullock, W.H. Quinazolinone derivatives as orally available ghrelin receptor antagonists for the treatment of diabetes and obesity. J. Med. Chem., 2007, 50, 5202-16.
64. Esler, W.P.; Rudolph, J.; Claus, T.H.; Tang, W.; Barucci, N.; Brown, S.E.; Bullock, W.; Daly, M.; Decarr, L.; Li, Y.; Milardo, L.; Molstad, D.; Zhu, J.; Gardell, S.J.; Livingston, J.N.; Sweet, L.J. Small-molecule ghrelin receptor antagonists improve glucose tolerance, suppress appetite, and promote weight loss. Endocrinology, 2007, 148, 5175-85.
65. Moulin, A.; Demange, L.; Ryan, J.; Mousseaux, D.; Sanchez, P.; Bergë, G.; Gagne, D.; Perrissoud, D.; Locatelli, V.; Torsello, A.; Galleyrand, J.C.; Fehrentz, J.A.; Martinez, J. New trisubstituted 1,2,4-triazole derivatives as potent ghrelin receptor antagonists. 3. Synthesis and pharmacological in vitro and in vivo evaluations. J. Med. Chem., 2008, 51, 689-93.
66. Beck, B.; Richy, S.; Stricker-Krongrad, A. Feeding response to ghrelin agonist and antagonist in lean and obese Zucker rats. Life Sci., 2004, 76, 473-8.
67. Halem, H.A.; Taylor, J.E.; Dong, J.Z.; Shen, Y.; Datta, R.; Abizaid, A.; Diano, S.; Horvath, T.; Zizzari, P.; Bluet-Pajot, M.T.; Epelbaum, J.; Culler, M.D. Novel analogs of ghrelin: physiological and clinical implications. Eur. J. Endocrinol., 2004, 151(Suppl 1), S71-5.
68. Holst, B.; Cygankiewicz, A.; Jensen, T.H.; Ankersen, M.; Schwartz, T.W. High constitutive signaling of the ghrelin receptor- -identification of a potent inverse agonist. Mol. Endocrinol., 2003, 17, 2201-10.
69. Holst, B.; Lang, M.; Brandt, E.; Bach, A.; Howard, A.; Frimurer, T.M.; Beck-Sickinger, A.; Schwartz, T.W. Ghrelin receptor inverse agonists: identification of an active peptide core and its interaction epitopes on the receptor. Mol. Phamacol., 2006, 70, 936-46.
70. Helmling, A.; Maasch, C.; Eulberg, D.; Buchner, K.; Schöder, W.; Lange, C.; Vonhoff, S.; Wlotzka, B.; Tschöp, M.H.; Rosewicz, S.; Klussmann, S. Inhibition of ghrelin action in vitro and in vivo by an RNA-Spiegelmer. Proc. Natl. Acad. Sci. USA, 2004, 101, 13174-9.
71. Zorrilla, E.P.; Iwasaki, S.; Moss, J.A.; Chang, J.; Otsuji, J.; Inoue, K.; Meijler, M.M; Janda, K.D. Vaccination against weight gain. Proc. Natl. Acad. Sci. USA, 2006, 103, 13226-31.
72. Kobelt, P.; Helmling, S.; Stengel, A.; Wlotzka, B.; Andresen, V.; Klapp, B.F.; Wiedenmann, B.; Klussmann, S.; Mönnikes, H. Antighrelin Spiegelmer NOX-B11 inhibits neurostimulatory and orexigenic effects of peripheral ghrelin in rats. Gut, 2006, 55, 788-92.
73. Shearman, L.P.; Wang, S.P.; Helmling, S.; Stribling, D.S.; Mazur, P.; Ge, L.; Wang, L.; Klussmann, S.; Macintyre, D.E.; Howard, A.D.; Strack, A.M. Ghrelin neutralization by a ribonucleic acid- SPM ameliorates obesity in diet-induced obese mice. Endocrinology, 2006, 147, 1517-26.
74. Bataille, D.; Gespach, C.; Tatemoto, K.; Marie, J.C.; Coudray, A.M.; Rosselin, G.; Mutt, V. Peptides, 1981, 2 (Suppl 2), S41-8.
75. Dakin, C.L.; Gunn, I.; Small, C.J.; Edwards, C.M.; Hay, D.L.; Smith, D.M.; Ghatei, M.A.; Bloom, S.R. Oxyntomodulin inhibits food intake in the rat. Endocrinology, 2001, 142, 4244-50.
76. Dakin, C.L.; Small, C.J.; Batterham, R.L.; Neary, N.M.; Cohen, M.A.; Patterson, M.; Ghatei, M.A.; Bloom, S.R. Peripheral oxyntomodulin reduces food intake and body weight gain in rats. Endocrinology, 2004, 145, 2687-95.
77. Cohen, M.A.; Ellis, S.M.; Le Roux, C.W.; Batterham, R.L.; Park, A.; Patterson, M.; Frost, G.S.; Ghatei, M.A.; Bloom SR. Oxyntomodulin suppresses appetite and reduces food intake in humans. J. Clin. Endocrinol. Metab., 2003, 88, 4696-701.
78. Wynne, K.; Park, A.J.; Small, C.J.; Meeran, K.; Ghatei, M.A.; Frost, G.S.; Bloom, S.R. Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial. Int. J. Obes. (Lond.), 2006, 30, 1729-36.
79. Wynne, K.; Bloom, S.R. The role of oxyntomodulin and peptide tyrosine-tyrosine (PYY) in appetite control. Nat. Clin. Pract. Endocrirnol. Metab., 2006, 2, 612-20.
80. Buemann, B.; Toubro, S.; Astrup, A. Effects of the two beta3- agonists, ZD7114 and ZD2079 on 24 hour energy expenditure and respiratory quotient in obese subjects. Int. J. Obes. Relat. Metab. Disord., 2000, 24, 1553-60.
81. Arch, J.R. beta(3)-Adrenoceptor agonists: potential, pitfalls and progress. Eur. J. Pharmacol., 2002, 440, 99-107.
82. Larsen, T.M.; Toubro, S.; van Baak, M.A.; Gottesdiener, K.M.; Larson, P., Saris, W.H.; Astrup, A. Effect of a 28-d treatment with L-796568, a novel beta(3)-adrenergic receptor agonist, on energy expenditure and body composition in obese men. Am. J. Clin. Nutr., 2002, 76, 780-8.
83. Redman, L.M.; de Jonge, L.; Fang, X.; Gamlin, B.; Recker, D.; Greenway, F.L.; Smith, S.; Ravussin, E. Lack of an effect of a novel beta3-adrenoceptor agonist, TAK-677, on energy metabolism in obese individuals: a double-blind, placebo-controlled randomized study. J. Clin. Endocrinol. Metab., 2007, 92, 527-31.
84. Álvarez-Castro, P.; Isidro, M.L.; García-Buela, J.; Leal-Cerro, A.; Broglio, F.; Tassone, F.; Ghigo, E.; Diëguez, C.; Casanueva, F.F.; Cordido, F. Marked GH secretion after ghrelin alone or combined with GH-releasing hormone (GHRH) in obese patients. Clin. Endocrinol. (Oxf.), 2004, 61, 250-5.
85. Cordido, F.; Álvarez-Castro, P.; Isidro, M.L.; Casanueva, F.F.; Diëguez, C. Comparison between insulin tolerance test, growth hormone (GH)-releasing hormone (GHRH), GHRH plus acipimox and GHRH plus GH-releasing peptide-6 for the diagnosis of adult GH deficiency in normal subjects, obese and hypopituitary patients. Eur. J. Endocrinol., 2003, 149, 117-22.
86. Mekala, K.C.; Tritos, N.A. Effects of recombinant human growth hormone therapy in obesity in adults - a meta-analysis. J. Clin. Endocrinol. Metab., 2009, 1, 130-7.
87. Ng, F.M.; Sun, J.; Sharma, L.; Libinaka, R.; Jiang, W.J.; Gianello, R. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm. Res., 2000, 53, 274-8.
88. Heffernan, M.; Summers, R.J.; Thorburn, A.; Ogru, E.; Gianello, R.; Jiang, W.J.; Ng, F.M. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology, 2001, 142, 5182-9.